You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on brain cancer.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
The firm said the financing enables it to progress with the development of an algorithm that would help detect the most common cancers.
The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.
While it was developed and validated for brain tumor classification, the workflow could be extended to other cancers where intraoperative histology is valuable.
The company in partnership with the University of Edinburgh recently completed a trial of the test involving 400 patients.
The Scottish researchers have cofounded ClinSpec Dx to commercialize an infrared spectroscopy platform that they said may enable more precise screening for brain cancer.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
The team developed their method to facilitate tumor cell movement through the blood-brain barrier for cancer biomarker detection. The method could eventually lead to the detection of brain cancer using a blood test.
Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.